Plasma c-Fn level before tPA therapy was independently associated with tPA-induced hemorrhagic transformation (HT) (59), whereas serum c-Fn level ≥3.6 mg/l within 3 h after stroke onset and before tPA therapy predicted PH after tPA therapy with a sensitivity of 100.0%, specificity of 60.0%, and negative predictive value of 100.0% (53). The gene discussed is PLAT; the disease is stroke disorder.